Skip to main content

Table 10 Prevalence rates of MetS according AHA/NHLB definition by new antipsychotic treatment, at baseline and after 3 months, (New-AP, CMD-set, N = 476)

From: Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

Visit 1 (Baseline)

    

Cohort

N

n

%

95% CI

New-Olz

206

79

38.4

31.7 to 45.4

New-Risp

69

24

34.8

23.7 to 47.2

New-Quet

33

18

54.6

36.4 to 71.9

New-Atyp

72

34

47.2

35.3 to 59.4

New-Typ

16

12

75.0

47.6 to 92.7

New-Comb

80

44

55.0

43.5 to 66.2

CMD-total

476

211

44.3

39.8 to 48.9

Visit 2 (month-3)

    

Cohort

N

n

%

95% CI

New-Olz

206

93

45.2

38.2 to 52.2

New-Risp

69

34

49.3

37.0 to 61.6

New-Quet

33

16

48.5

30.8 to 66.5

New-Atyp

72

34

47.2

35.3 to 59.4

New-Typ

16

11

68.8

41.3 to 89.0

New-Comb

80

48

60.0

48.4 to 70.8

CMD-total

476

236

49.6

45.0 to 54.2

  1. Abbreviations: AHA/NHLB = American Heart Association/National Heart, Lung and Blood Institute
  2. CI = confidence interval, CMD = complete metabolic data; MetS = metabolic syndrome; NCEP-ATP III = National Cholesterol Education Program, Adult Treatment Panel 3rd report; New-AP = new antipsychotic treatment